Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 4
2007 2
2009 2
2010 5
2012 4
2013 3
2014 4
2015 4
2017 2
2018 5
2019 3
2020 3
2021 5
2022 7
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L. Sircar A, et al. Among authors: tao j. Leukemia. 2023 Oct;37(10):2094-2106. doi: 10.1038/s41375-023-02006-8. Epub 2023 Aug 19. Leukemia. 2023. PMID: 37598282 Free PMC article.
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas.
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Zhang X, et al. Among authors: tao j. Cancer Cell. 2023 Jun 12;41(6):1198. doi: 10.1016/j.ccell.2023.05.003. Cancer Cell. 2023. PMID: 37311416 No abstract available.
MCL1 as a therapeutic vulnerability in Burkitt lymphoma.
Yuan R, Wang MY, Bi C, Zhao X, Tao J. Yuan R, et al. Among authors: tao j. Leukemia. 2023 Apr;37(4):934-937. doi: 10.1038/s41375-023-01827-x. Epub 2023 Feb 2. Leukemia. 2023. PMID: 36732564 No abstract available.
Frontline treatment approaches in TP53-aberrant mantle cell lymphoma.
Shah NN, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper TC, Hussaini M, Tao J, Chavez JC, Isenalumhe L, Gaballa S, Saeed H, Bello C, Sokol L, Pinilla-Ibarz J, Shah BD. Shah NN, et al. Among authors: tao j. Leuk Lymphoma. 2023 Jan;64(1):230-233. doi: 10.1080/10428194.2022.2131407. Epub 2022 Oct 27. Leuk Lymphoma. 2023. PMID: 36301721 No abstract available.
61 results